XPHOZAH
XPHOZAH (tenapanor) is an oral small-molecule therapy developed by Ardelyx that reduces serum phosphorus in dialysis-dependent chronic kidney disease (CKD) by blocking the NHE3 sodium/hydrogen exchanger in the gut lining. In patients on dialysis, the kidneys can no longer excrete phosphorus, causing hyperphosphatemia that accelerates vascular calcification and cardiovascular mortality. Tenapanor acts locally in the gut without systemic absorption, closing the paracellular channels through which dietary phosphorus is absorbed; it is approved as a stand-alone or add-on to phosphate binders, with an ongoing pediatric label-expansion program.
Upcoming catalysts
Programs
Chronic Kidney Disease
Hyperphosphatemia is a near-universal complication of dialysis-dependent CKD driven by the inability of failed kidneys to excrete phosphorus; uncontrolled serum phosphorus accelerates vascular calcification and cardiovascular mortality. XPHOZAH is approved in adults as a stand-alone or add-on to phosphate binders; this program initiates a pediatric Phase 3 study in CKD hyperphosphatemia, a procedural milestone in the pediatric label-extension path.